Cornerstone Pharmaceutical-B: Signing with Kangsheng Global Signing Hematology Consolidation Strategic Cooperation Framework Agreement

On July 27, 2022, the cornerstone pharmaceutical industry-B (02616.HK) of the listed company listed on the Hong Kong stock market announced that it signed a strategic cooperation framework agreement with Kangsheng Global (09960.HK).

Picture source: cornerstone pharmaceutical officer Wei

According to the agreement, the two sides have reached a number of cooperation intentions on the precision diagnosis and treatment of hematological tumors, including: jointly carry out related educational activities, enhance the concept of precise testing and treatment in the field of hematological tumors, and jointly explore genetic mutations such as IDH1 and other gene mutations in patients with acute myeloid leukemia (AML) patients with IDH1 The detection can be available and standardized to help more Chinese patients in the world's first drug Tuoshuwo® (Avinib tablet).

According to the data, Tuoshuwo® is a oral targeted inhibitor for IDH1 mutant enzymes. It has been approved to treat patients with adult recurrence or refractory acute myeloid leukemia (R/R AML) patients who carry IDH1 susceptible mutations (R/R AML). And in June this year, the first batch of prescriptions was officially provided for more than 50 provinces and cities across the country and DTP pharmacies outside the hospital and out -of -hospital DTP pharmacies.

In addition, many new indications in Tuoshuo ® are actively exploring, including the first -line therapy of the newly diagnosed IDH1 mutant AML adult patient, for local advanced or metastatic bile duct cancer patients for IDH1 mutations, and for treatment and carrying ADH1's recurrence/refractory bone marrow hyperplasia abnormal syndrome (MDS) and so on.

Regarding this cooperation, the two sides will enhance the accurate testing and treatment concepts in the field of hematological tumors by giving play to their respective advantages, increasing the availability and standardization of gene testing such as IDH1 in patients with acute myeloid leukemia. Patients with targeted drugs Topshwo®.

- END -